Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2024-04-12 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
To Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Enlivex Therapeutics will host a conference call and webcast to discuss topline results from a Phase II trial. It details the date and time of the call and provides registration links. This type of announcement, which publicizes an upcoming event to discuss results (often earnings or clinical trial data), is typically classified as an Earnings Release (ER) if it were the actual results, or a general announcement. Since the core purpose is to announce a future event (a call) where results will be discussed, and it is not the full transcript (CT), the full financial report (10-K/IR), or a presentation (IP), it most closely aligns with an Earnings Release (ER) which often precedes or accompanies the detailed discussion, or it could be seen as a general announcement. However, given the context of clinical trial results being discussed on a call, it functions similarly to an Earnings Release announcement, focusing on key performance updates. Since it is an announcement about a future event to discuss results, and not the results themselves, it is often categorized as an ER or RNS. Given the focus on discussing 'topline results' which are key performance indicators, ER is a strong candidate, but because it is purely an announcement of a call, and not the release of the results document itself, it fits the 'announcement' criteria. If the document were longer and contained the actual results summary, ER would be certain. As a short announcement about a call to discuss results, it is often grouped with ER or RNS. Given the options, and the fact that it is a time-sensitive announcement regarding performance data discussion, ER is the most specific fit among the performance-related codes, although RPA or RNS are also plausible if it were purely administrative. Since it is announcing the discussion of key performance data, I will lean towards ER as the intent is to inform investors about the upcoming performance update event.
2024-04-12 English
To Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Report Publication Announcement Classification · 1% confidence The document is very short (1787 characters) and explicitly states, "Attached hereto is a report on*press release* *PR11042024_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a press release/report), rather than the full content of that report. According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). The filing is made to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE), which aligns with general regulatory reporting, but RPA is the most specific category for this announcement format.
2024-04-12 English
Form 6-K- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Regulatory Filings Classification · 1% confidence The document is explicitly identified as a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934', which is a Form 6-K filing. Form 6-K filings are generally used by foreign private issuers to report material information to the SEC, often including press releases or other material events that are not required to be reported on a periodic basis like a 10-K. The content primarily consists of announcing topline results from a Phase II trial (Exhibit 99.1) and posting an updated investor presentation (Exhibit 99.2). Since the document itself is the official SEC filing (Form 6-K) that contains these announcements, and it is not a standard periodic report (10-K, IR) or a simple announcement of a report's publication (RPA), it falls best under the general 'Regulatory Filings' category (RNS) as Form 6-K is a specific type of regulatory filing not explicitly listed, but RNS serves as the appropriate fallback for miscellaneous SEC filings that aren't the core reports listed (10-K, IR, ER, etc.). However, given the context of the provided definitions, RNS is the most suitable general regulatory filing category for a Form 6-K that is not an earnings release or a specific report type listed.
2024-04-11 English
Form 6-K- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Regulatory Filings Classification · 1% confidence The document explicitly mentions 'Immediate Report' under 'Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000'. It also references an attached file, '*6k* 6K11042024_isa.pdf'. The presence of '6K' (which typically refers to an SEC Form 6-K, an 'Information Statement' for foreign private issuers) and the nature of the document being an 'Immediate Report' announcing an attachment, strongly suggests this is a general regulatory filing announcement rather than the full content of a specific report type like 10-K or IR. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for a general, immediate regulatory disclosure that doesn't fit the specific definitions like ER, IR, or DIRS, especially since it's announcing the filing of a Form 6-K.
2024-04-11 English
6-k -FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023
Annual Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains the company's audited consolidated financial statements for the year ended December 31, 2023, including the Report of the Independent Registered Public Accounting Firm. While it is filed as a 6-K, the core content is the annual financial reporting and audit results for a foreign private issuer. According to the classification rules, since it contains the full audited financial statements and audit report, it is classified as an Annual Report (10-K equivalent for foreign issuers). FY 2023
2024-03-30 English
6-k -FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023
Report Publication Announcement Classification · 1% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' under Israeli Securities Authority regulations. It mentions an attached file named '*6k29032024_isa.pdf*' and references the SEC Form 6-K, which is used for reporting material events by foreign private issuers. Since this document is short (1880 chars) and serves primarily to announce the publication of an attached periodic report (the 6-K PDF), it fits the definition of a Report Publication Announcement (RPA). It is not the comprehensive Interim Report (IR) itself, but the announcement of its filing.
2024-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.